KCM
GYRE icon

Kynam Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Kynam Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,004
Closed -$43.4K – 27
2023
Q3 		$43.4K Buy
6,004
+12
+0.2% +$80 0.01% 30
2023
Q2 		$31.6K Hold
5,992
– – ﹤0.01% 26
2023
Q1 		$18.6K Sell
5,992
-6,073
-50% -$23.1K ﹤0.01% 35
2022
Q4 		$47.7K Buy
12,065
+40
+0.3% +$163 0.01% 31
2022
Q3 		$45K Sell
12,025
-433
-3% -$5.5K 0.01% 36
2022
Q2 		$166K Sell
12,458
-1,687
-12% -$11.2K 0.04% 33
2022
Q1 		$70K Sell
14,145
-654
-4% -$3.24K 0.02% 33
2021
Q4 		$101K Buy
+14,799
New +$253K 0.05% 30

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Kynam Capital Management's GYRE Position: Q4 2023 in Review

Kynam Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 6,004 shares — an estimated $43.4K sold.

Kynam Capital Management first reported a position in GYRE in Q4 2021 and held it in 8 quarters. The position peaked at $166K in Q2 2022. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Kynam Capital Management reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Kynam Capital Management sold 6,004 Gyre Therapeutics shares in Q4 2023, an estimated $43.4K.
  • Kynam Capital Management first reported a position in Gyre Therapeutics in Q4 2021 and held it in 8 quarters.
  • Kynam Capital Management's Gyre Therapeutics position peaked at $166K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.